Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bazedoxifene/Conjugated Estrogens for Prevention of Endometrial Hyperplasia and Osteoporosis
NCT00242710Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bazedoxifene in endometrial hyperplasia (EH) and osteoporosis (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Hyperplasia at Screening, Percentage of Participants With Hyperplasia at Month 12 and 4 more. Started Sep 2005; status: completed.
02
Drugs
bazedoxifene
03
Conditions
endometrial hyperplasia (EH)osteoporosis
Beyond the preview
Go deeper on NCT00242710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242710.